rare type of small cell lung cancer that primarily affects younger people who have never ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t ...

American Cancer Society: “How is non-small cell lung cancer staged?” “Surgery for non-small cell lung cancer,” “Treatment choices by stage for non-small cell lung cancer,” “Radiation ...

New, Rare Type of Small Cell Lung Cancer Identified Sep. 11 ... Aug. 23, 2024 — A team of researchers has created a digital pathology platform based on artificial intelligence.

Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including targeted therapy. Teamwork: A Multidisciplinary Approach to ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and ...

Opens in a new tab or window EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy ...

More than 80% of patients with lung cancer receive care in their communities, but this can leave them vulnerable to gaps in care quality and delivery. Amivantamab's role in non–small cell lung ...